Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

Worldwide, patients with HoFH are diagnosed too late, undertreated, and at high premature
ASCVD risk. Greater use of multi-LLT regimens is associated with lower LDL cholesterol
levels and better outcomes. Significant global disparities exist in treatment regimens,
control of LDL cholesterol levels, and cardiovascular event-free survival, which demands
a critical re-evaluation of global health policy to reduce inequalities and improve
outcomes for all patients with HoFH.